$KRTL KRTL Biotech Highlights Anti-Allergy and Res
Post# of 35
(Total Views: 54)
Posted On: 11/06/2025 12:53:55 PM
$KRTL KRTL Biotech Highlights Anti-Allergy and Respiratory Product Capabilities to Address Global Market Needs
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=498971
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced a category spotlight on anti-allergy and respiratory health products, reinforcing its strategic intent to address rising global demand for accessible, effective treatments across both developed and emerging healthcare markets.
The global allergy treatment market is projected to reach USD 35.8 billion by 2028, according to The Insight Partners, driven by increased urban exposure to pollutants, climate-linked allergen patterns, and the broader recognition of allergic conditions as a public health priority. As allergy prevalence grows, so does the need for scalable, high-quality therapeutics—particularly antihistamines and bronchodilators that are cost-effective and widely accessible.
Through its partnership with Industria Químico-Farmacéutica SIGMA Corp. in Bolivia, KRTL Biotech benefits from vertically integrated manufacturing capabilities and access to a broad portfolio of anti-allergy formulations. SIGMA’s GMP-compliant facilities support scalable production of active pharmaceutical ingredients (APIs) and finished dosage forms that meet therapeutic needs in pediatrics, adult care, and chronic respiratory support.
"Our anti-allergy line has been developed with the needs of everyday patients in mind—from pediatric relief to adult care," said Patricia Wilstermann, CEO of SIGMA. "By producing high-quality, affordable antihistamines and bronchodilators, SIGMA is proud to contribute to the growing demand for respiratory support solutions, both nationally and now internationally through our work with KRTL."
Representative products in SIGMA’s anti-allergy category include:
Cetirizine 10 mg tablets
Chlorphenamine in injectables and tablet form
KRTL Biotech also maintains access to select APIs such as loratadine, cetirizine, and salbutamol, allowing the Company to reinforce supply chain stability in a market often affected by production volatility and regional dependencies.
These capabilities support both commercial and public-sector distribution strategies. The Company is evaluating pathways for select anti-allergy and respiratory products to enter U.S. and LATAM markets through Over-the-Counter (OTC) Monograph compliance, Abbreviated New Drug Applications (ANDAs), and regional tender opportunities.
"KRTL's pharmaceutical strategy is focused on product classes that are both medically essential and commercially scalable," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This category demonstrates strong global need, and with SIGMA's proven capacity, we are well-positioned to support respiratory health initiatives across multiple geographies."
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=498971
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced a category spotlight on anti-allergy and respiratory health products, reinforcing its strategic intent to address rising global demand for accessible, effective treatments across both developed and emerging healthcare markets. The global allergy treatment market is projected to reach USD 35.8 billion by 2028, according to The Insight Partners, driven by increased urban exposure to pollutants, climate-linked allergen patterns, and the broader recognition of allergic conditions as a public health priority. As allergy prevalence grows, so does the need for scalable, high-quality therapeutics—particularly antihistamines and bronchodilators that are cost-effective and widely accessible.
Through its partnership with Industria Químico-Farmacéutica SIGMA Corp. in Bolivia, KRTL Biotech benefits from vertically integrated manufacturing capabilities and access to a broad portfolio of anti-allergy formulations. SIGMA’s GMP-compliant facilities support scalable production of active pharmaceutical ingredients (APIs) and finished dosage forms that meet therapeutic needs in pediatrics, adult care, and chronic respiratory support.
"Our anti-allergy line has been developed with the needs of everyday patients in mind—from pediatric relief to adult care," said Patricia Wilstermann, CEO of SIGMA. "By producing high-quality, affordable antihistamines and bronchodilators, SIGMA is proud to contribute to the growing demand for respiratory support solutions, both nationally and now internationally through our work with KRTL."
Representative products in SIGMA’s anti-allergy category include:
Cetirizine 10 mg tablets
Chlorphenamine in injectables and tablet form
KRTL Biotech also maintains access to select APIs such as loratadine, cetirizine, and salbutamol, allowing the Company to reinforce supply chain stability in a market often affected by production volatility and regional dependencies.
These capabilities support both commercial and public-sector distribution strategies. The Company is evaluating pathways for select anti-allergy and respiratory products to enter U.S. and LATAM markets through Over-the-Counter (OTC) Monograph compliance, Abbreviated New Drug Applications (ANDAs), and regional tender opportunities.
"KRTL's pharmaceutical strategy is focused on product classes that are both medically essential and commercially scalable," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This category demonstrates strong global need, and with SIGMA's proven capacity, we are well-positioned to support respiratory health initiatives across multiple geographies."
(0)
(0)